Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes

Biologic treatment of type 1 diabetes (T1D) with agents including anti-CD3 (otelixizumab and teplizumab), anti-CD20 (rituximab), LFA3Ig (alafacept), and CTLA4Ig (abatacept) results in transient stabilization of insulin C-peptide, a surrogate for endogenous insulin secretion. With the goal of inducin...

Descripción completa

Detalles Bibliográficos
Autores principales: Linsley, Peter S., Greenbaum, Carla J., Rosasco, Mario, Presnell, Scott, Herold, Kevan C., Dufort, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477779/
https://www.ncbi.nlm.nih.gov/pubmed/29925930
http://dx.doi.org/10.1038/s41435-018-0032-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477779/
https://www.ncbi.nlm.nih.gov/pubmed/29925930
http://dx.doi.org/10.1038/s41435-018-0032-1

Ejemplares similares